Amicus Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a FOLD research report →
Companyamicusrx.com
Amicus Therapeutics, Inc. , a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data.
- CEO
- Bradley L. Campbell
- IPO
- 2007
- Employees
- 499
- HQ
- Philadelphia, PA, US
Price Chart
Valuation
- Market Cap
- $4.55B
- P/E
- -165.17
- P/S
- 7.17
- P/B
- 16.33
- EV/EBITDA
- 89.56
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 87.91%
- Op Margin
- 5.17%
- Net Margin
- -4.27%
- ROE
- -12.02%
- ROIC
- -645.68%
Growth & Income
- Revenue
- $634.21M · 20.05%
- Net Income
- $-27,110,000 · 51.68%
- EPS
- $-0.09 · 51.17%
- Op Income
- $34.49M
- FCF YoY
- 179.72%
Performance & Tape
- 52W High
- $14.50
- 52W Low
- $5.51
- 50D MA
- $14.40
- 200D MA
- $10.88
- Beta
- 0.48
- Avg Volume
- 4.15M
Get TickerSpark's AI analysis on FOLD
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 27, 26 | WHEELER CRAIG A | sell | 84,631 |
| Apr 27, 26 | WHEELER CRAIG A | sell | 30,000 |
| Apr 27, 26 | WHEELER CRAIG A | sell | 16,236 |
| Apr 27, 26 | WHEELER CRAIG A | sell | 19,473 |
| Apr 27, 26 | WHEELER CRAIG A | sell | 18,574 |
| Apr 27, 26 | WHEELER CRAIG A | sell | 36,111 |
| Apr 27, 26 | WHEELER CRAIG A | sell | 45,423 |
| Apr 27, 26 | WHEELER CRAIG A | sell | 30,474 |
| Apr 27, 26 | WHEELER CRAIG A | sell | 42,467 |
| Apr 27, 26 | WHEELER CRAIG A | sell | 74,872 |
Our FOLD Coverage
We haven't published any research on FOLD yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate FOLD Report →